Cybin (CYBN) and Its Rivals Critical Analysis

Cybin (NYSE:CYBN) is one of 1,002 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare Cybin to related businesses based on the strength of its risk, earnings, dividends, institutional ownership, analyst recommendations, profitability and valuation.

Analyst Ratings

This is a breakdown of current ratings for Cybin and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0	0	3	0	3.00
Cybin Competitors	7253	19802	45686	1087	2.55

Cybin currently has a consensus target price of $50.50, indicating a potential upside of 382.33%. As a group, “Pharmaceutical preparations” companies have a potential upside of 63.19%. Given Cybin’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Cybin is more favorable than its rivals.

Profitability

This table compares Cybin and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-42.36%	-40.56%
Cybin Competitors	-3,669.29%	-260.55%	-31.24%

Institutional & Insider Ownership

17.9% of Cybin shares are held by institutional investors. Comparatively, 44.3% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 15.0% of Cybin shares are held by insiders. Comparatively, 14.0% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Cybin has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Comparatively, Cybin’s rivals have a beta of 0.88, suggesting that their average stock price is 12% less volatile than the S&P 500.

Valuation & Earnings

This table compares Cybin and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Cybin	N/A	-$57.88 million	-52.35
Cybin Competitors	$9.70 billion	$148.47 million	-4.53

Cybin’s rivals have higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Cybin rivals beat Cybin on 7 of the 13 factors compared.

About Cybin

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.